NCT Number: NCT05493930
A Lymph Node Metastasis Predictor (LN-MASTER) in Rectal Cancer
In this study, we aim to develop and validate an easy-to-use machine learning prediction model to preoperatively identify the lymph node metastasis status for rectal cancer patients by using these clinical data from three hospitals.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Observational
About this study
In this study, participants were recruited from the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College (development set), Changhai Hospital, Naval Medical University (external validation set 1), and the Second Affiliated Hospital of Harbin Medical University (external validation set 2), between January 1, 2016, and December 31, 2020. According to the inclusion criteria, participants who (a) were in American Joint Committee on Cancer (AJCC) stages I -III rectal cancer and (b) underwent radical surgery were recruited. In contrast, the exclusion criteria were as follows: (a) other malignancies, (b) received treatment with endoscopic submucosal dissection (ESD), (c) metastatic lesions, (d) did not undergo lymph node dissection, (e) had unavailable assessed lymph node status, and (f) received neoadjuvant therapy. The lymph node metastasis (LNM) status was determined based on the pathological diagnosis of the surgical specimens.
Clinicopathological features included sex, age, body mass index (BMI), comorbidity, distance from the lower edge of the tumor to the anus, carcinoembryonic antigen (CEA) levels, carbohydrate antigen 19-9 (CA19-9) levels, tumor size, degree of tumor differentiation, tumor histology, vascular or lymphatic vessel invasion, AJCC T stage, clinical diagnosis of LNM, and the pathological diagnosis of LNM. Among these, sex, age, BMI, and comorbidities of each participant, such as diabetes, hypertension, hyperlipidemia, and other chronic systemic diseases, were extracted from the electronic hospital information system. Preoperative CEA and CA19-9 levels were obtained from hematological examinations at the time of rectal cancer diagnosis. The distance from the lower edge of the tumor to the anus, differentiation degree, and tumor histology were recorded based on the results of endoscopy and endoscopic biopsies. The tumor diameter and clinical diagnosis of LNM were defined using preoperative pelvic MRI or CT. The diagnosis of vascular invasion, lymphatic vessel invasion, and LNM was based on postoperative pathological diagnosis.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- American Joint Committee on Cancer (AJCC) stages I -III rectal cancer
- underwent radical surgery
Exclusion criteria
- other malignancies
- received treatment with endoscopic submucosal dissection (ESD)
- metastatic lesions
- did not undergo lymph node dissection
- had unavailable assessed lymph node status
- received neoadjuvant therapy
Treatment and study plan
Primary outcomes
-
diagnosis of lymph node metastasis
Time frame: through study completion, an average of 1 month
The lymph node metastasis (LNM) status was determined based on the pathological diagnosis of the surgical specimens.
Sponsors and collaborators
Lead sponsor
Peking Union Medical College
Other
Collaborators
- Changhai Hospital
- The Second Affiliated Hospital of Harbin Medical University
Registry information
Official study title
An Easy-to-use Artificial Intelligence Preoperative Lymph Node Metastasis Predictor (LN-MASTER) in Rectal Cancer Based on a Privacy-preserving Computing Platform: Multicenter Retrospective Cohort Study
Important dates
- Study start
- 2010
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Aug 9, 2022
- Registry last updated
- Aug 9, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Project HERO: Health Empowerment & Recovery Outcomes
NCT03345563
Bladder Cancer, Colon Cancer
New Brunswick, New Jersey, United States
View Trial DetailsEfficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening
NCT02738359
Colon Cancer, Colonic Diseases
Pessac, Aquitaine, France
View Trial DetailsA Clinical Evaluation of AI Solutions Developed in the CHAIMELEON Project for Cancer: Prostate, Lung, Breast, Colon and Rectum
NCT06950996
Breast Cancer, Breast Diseases
Valencia, Spain
View Trial DetailsRobotic Low Rectum Anterior Resection
NCT04015804
Colorectal Neoplasms, Digestive System Diseases
Brussels, Belgium
View Trial Details